DSM-Firmenich is a high-quality specialty chemicals company focused on inelastic, high-margin nutrition, health, and beauty ingredients. Following the divestment of its volatile animal nutrition segment, DSM-Firmenich now boasts a robust A-rated balance sheet, strong FCF, and a well-covered 3%+ dividend. Despite historical premium valuations, I assign a forward P/E of 17-18x, reflecting justified but moderate premiumization versus peers, with a price target of €67.8/share.
DSM-Firmenich AG (DSFIY) Q1 2026 Sales/Trading Call Transcript
DSM-Firmenich AG (DSFIY) Shareholder/Analyst Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 2.11M | $12.61M | $12.83M | $219,336.4 | 1.74% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 2,700 | $16,227 | $16,416 | $189 | 1.16% |
Daniel L. Lippincott Karpus Management Inc. | 940,172 | $5.3M | $5.72M | $412,645.42 | 7.78% |
Bulldog Investors Bulldog Investors LLP | 3.37M | $19.7M | $20.51M | $816,509.63 | 4.15% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 1.48M | $8.89M | $8.98M | $84,142.68 | 0.95% |